Myasthenia gravis: newer therapies offer sustained improvement.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24186889.
- Also identified by DOI 10.3949/ccjm.80a.13044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Myasthenia gravis is a prototypical antibody-mediated autoimmune neuromuscular disorder. Treatments have improved over the past 30 years, leading to significantly fewer deaths and better quality of life. Future research should further elucidate its pathogenesis, reveal better ways to diagnose it, and yield new treatments.
Medical subject headings
- Immunotherapy
- Myasthenia Gravis
- Plasmapheresis